コンテンツへスキップ
Merck
  • A large genomic deletion leads to enhancer adoption by the lamin B1 gene: a second path to autosomal dominant adult-onset demyelinating leukodystrophy (ADLD).

A large genomic deletion leads to enhancer adoption by the lamin B1 gene: a second path to autosomal dominant adult-onset demyelinating leukodystrophy (ADLD).

Human molecular genetics (2015-02-24)
Elisa Giorgio, Daniel Robyr, Malte Spielmann, Enza Ferrero, Eleonora Di Gregorio, Daniele Imperiale, Giovanna Vaula, Georgios Stamoulis, Federico Santoni, Cristiana Atzori, Laura Gasparini, Denise Ferrera, Claudio Canale, Michel Guipponi, Len A Pennacchio, Stylianos E Antonarakis, Alessandro Brussino, Alfredo Brusco
要旨

Chromosomal rearrangements with duplication of the lamin B1 (LMNB1) gene underlie autosomal dominant adult-onset demyelinating leukodystrophy (ADLD), a rare neurological disorder in which overexpression of LMNB1 causes progressive central nervous system demyelination. However, we previously reported an ADLD family (ADLD-1-TO) without evidence of duplication or other mutation in LMNB1 despite linkage to the LMNB1 locus and lamin B1 overexpression. By custom array-CGH, we further investigated this family and report here that patients carry a large (∼660 kb) heterozygous deletion that begins 66 kb upstream of the LMNB1 promoter. Lamin B1 overexpression was confirmed in further ADLD-1-TO tissues and in a postmortem brain sample, where lamin B1 was increased in the frontal lobe. Through parallel studies, we investigated both loss of genetic material and chromosomal rearrangement as possible causes of LMNB1 overexpression, and found that ADLD-1-TO plausibly results from an enhancer adoption mechanism. The deletion eliminates a genome topological domain boundary, allowing normally forbidden interactions between at least three forebrain-directed enhancers and the LMNB1 promoter, in line with the observed mainly cerebral localization of lamin B1 overexpression and myelin degeneration. This second route to LMNB1 overexpression and ADLD is a new example of the relevance of regulatory landscape modifications in determining Mendelian phenotypes.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
塩化ナトリウム, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
塩酸 溶液, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
デオキシコール酸ナトリウム, BioXtra, ≥98.0% (dry matter, NT)
Sigma-Aldrich
塩化ナトリウム 溶液, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
塩化ナトリウム, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
塩化ナトリウム 溶液, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
塩酸, 36.5-38.0%, BioReagent, for molecular biology
Supelco
塩酸 溶液, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
塩化ナトリウム, JIS special grade, ≥99.5%
Sigma-Aldrich
塩酸, SAJ first grade, 35.0-37.0%
Sigma-Aldrich
塩化ナトリウム 溶液, BioUltra, for molecular biology, ~5 M in H2O
Sigma-Aldrich
塩化ナトリウム, 99.999% trace metals basis
Sigma-Aldrich
塩化ナトリウム, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
塩酸 溶液, 1 M
Sigma-Aldrich
塩酸, JIS special grade, 35.0-37.0%
SAFC
デオキシコール酸ナトリウム
Sigma-Aldrich
デオキシコール酸, ≥98% (HPLC)
Sigma-Aldrich
塩酸 溶液, ~6 M in H2O, for amino acid analysis
Sigma-Aldrich
塩酸 溶液, 0.1 M
Sigma-Aldrich
塩酸 溶液, 6 M
Sigma-Aldrich
塩酸 溶液, 12 M
Sigma-Aldrich
塩化水素 溶液, 3 M in cyclopentyl methyl ether (CPME)
Sigma-Aldrich
塩化ナトリウム, SAJ first grade, ≥99.0%
Sigma-Aldrich
塩酸 溶液, 2 M
Sigma-Aldrich
デオキシコール酸, ≥99.0% (T)
Sigma-Aldrich
デオキシコール酸ナトリウム, ≥97% (titration)
Sigma-Aldrich
塩化ナトリウム, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
塩酸 溶液, 0.5 M
Sigma-Aldrich
塩化ナトリウム, BioPerformance Certified, ≥99% (titration), suitable for insect cell culture, suitable for plant cell culture
Sigma-Aldrich
塩化ナトリウム, AnhydroBeads, −10 mesh, 99.999% trace metals basis